Advertisement
U.S. markets closed

BioNTech SE (BNTX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
92.25-0.72 (-0.77%)
At close: 04:00PM EDT
91.61 -0.64 (-0.69%)
After hours: 05:13PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close92.97
Open92.90
Bid92.18 x 100
Ask92.41 x 100
Day's Range92.20 - 93.84
52 Week Range85.21 - 131.52
Volume432,992
Avg. Volume693,336
Market Cap21.93B
Beta (5Y Monthly)0.23
PE Ratio (TTM)22.23
EPS (TTM)4.15
Earnings DateMay 06, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateJun 02, 2022
1y Target Est121.93
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-20% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for BNTX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • BioNTech SE
    Analyst Report: BioNTech SEBioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Covid vaccine Comirnaty is its first commercialized product.
    Rating
    Fair Value
    Economic Moat
    8 days agoMorningstar
View more
  • Barrons.com

    This Vaccine Maker Sits on Cash Almost Equal to Its Market Value

    This biotechnology company has nearly 90% of its market value in cash and investments but is being shunned by investors even as they gravitate to the sector this year. The company is BioNTech (Ticker BNTX). It partnered with Pfizer to produce the leading Covid vaccine, Comirnaty, whose original messenger RNA technology was developed by BioNTech.

  • Reuters

    UPDATE 2-BioNTech gets US agency notice over default on COVID vaccine royalties

    BioNTech said on Monday the U.S. National Institutes of Health has sent a notice to the German company regarding default on the payment of royalties and other amounts related to its COVID-19 vaccine. BioNTech, which partnered with U.S. pharma giant Pfizer for its COVID-19 vaccine, however, said it disagreed with the positions being taken by the NIH and intends to defend against all allegations of breach. Spokespersons for the U.S. NIH did not immediately respond to Reuters' request for a comment.

  • Simply Wall St.

    BioNTech Full Year 2023 Earnings: Misses Expectations

    BioNTech ( NASDAQ:BNTX ) Full Year 2023 Results Key Financial Results Revenue: €3.82b (down 78% from FY 2022). Net...